Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cuprimine-Generic (penicillamine) is a copper chelating agent, small molecule drug candidate, which is being evauated for the treatment of Wilson's disease.
Product Name : Cuprimine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Penicillamine-Generic is a chelating agent used in the treatment of Wilson’s disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy.
Product Name : Penicillamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Secures Approval for Penicillamine Capsules, Generic of Cuprimine®
Details : Generic version of penicillamine is a copper chelating agent, small molecule drug candidate, which approved by USFDA for the treatment of Wilson's disease.
Product Name : Cuprimine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2020
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Penicillamine Capsules, USP (generic for Cuprimine®), a chelating agent recommended for the removal of excess copper in patients with Wilson's disease also in cystinuria, and in patients with severe, active rheumatoid arthritis.
Product Name : Pencillamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Penicillamine Tablets USP
Details : Penicillamine tablets USP, 250 mg, are the generic equivalent of Depen tablets, 250 mg, of Mylan and indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to conv...
Product Name : Depen-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval for Penicillamine Tablets USP
Details : Lupin has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P.
Product Name : Depen-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peficitinib,Hydroxychloroquine Sulphate,Sulfasalazine,Gold,Penicillamine,Lobenzarit,Actarit,Bucillamine,Iguratimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2018
Lead Product(s) : Peficitinib,Hydroxychloroquine Sulphate,Sulfasalazine,Gold,Penicillamine,Lobenzarit,Actarit,Bucillamine,Iguratimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Trientine TetraHCl
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2018
Lead Product(s) : Penicillamine,Trientine TetraHCl
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ascorbic Acid,Penicillamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Dialysis Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 11, 2017
Lead Product(s) : Ascorbic Acid,Penicillamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Dialysis Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Post Marketing Surveillance Study of Cuprimine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2011
Lead Product(s) : Penicillamine,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable